David Beckham co-founded health brand IM8, which accounts for nearly all Prenetics revenue. Rosin will lead finance.
Prenetics (Nasdaq: PRE) announced Brian J. Rosin will become CFO effective December 31, 2026, succeeding Stephen Lo. Rosin, currently CFO of IM8, will lead global finance. IM8, co-founded by David Beckham, generates nearly all of Prenetics' revenue. The company will report Q3 2026 results on November 18, 2026, with a live-streamed earnings event.
How this was made
The 30-second read
Why it matters
The appointment signals a strategic shift toward U.S. investors and may improve reporting quality, potentially attracting more capital.
Market read
Executive change is a primary corporate disclosure; modest trading relevance for PRE.
What to watch
Rosin's prior experience in e‑commerce and consumer health could accelerate IM8's expansion, which the market may undervalue.
Background
Prenetics, a Nasdaq‑listed consumer health company, is consolidating its finance function in the U.S. as IM8 now drives nearly all revenue.
Ticker impact
Prenetics announced the appointment of Brian J. Rosin as CFO effective Dec 31 2026, completing a planned finance leadership transition.
potential modest upside as investors view the U.S.-based finance team as a positive for scalability
Executive appointments are primary disclosures; the market typically reacts modestly unless the individual brings a dramatic strategic shift.
Market effects
Highlights the consumer health sector's focus on U.S. capital markets and financial transparency.
May boost investor confidence in U.S.-listed health‑tech stocks.
Limited to Prenetics and its IM8 brand; no broader macro impact.
Counterpoint
The CFO change may be a cosmetic move; underlying growth challenges could still pressure the stock.
Key entities
- companyPrenetics Global Limited
Nasdaq‑listed consumer health firm, parent of IM8.
- executiveBrian J. Rosin
New CFO of Prenetics, previously CFO of IM8.



